Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Hypoglycemia is a feared adverse effect of antihyperglycemic therapy due to its unpleasant symptoms and the associated medical risk of each episode, which interfere with daily activities and impose psychosocial stress on both patients and their caregivers. Beyond these concerns, numerous studies have found an association between hypoglycemia episodes and hypoglycemia burden with subsequent risk for adverse cardiovascular (CV) outcomes, leading to the hypothesis that avoidance of hypoglycemia in the treatment of patients with type 2 diabetes (T2D) may mitigate CV risk.1-7 However, it remains a matter of debate whether the observed associations represent a direct causal link between hypoglycemia and increased risk for adverse CV events or mortality or merely highlight a frail phenotype of patients who are susceptible to both events.1,8,9

This publication has 21 references indexed in Scilit: